<DOC>
	<DOCNO>NCT00518011</DOCNO>
	<brief_summary>This 2 arm study ass efficacy safety Tarceva plus gemcitabine , compare gemcitabine alone , treatment chemotherapy-naive patient advance non-small cell lung cancer . Patients randomize receive either Tarceva 150mg po daily plus gemcitabine day 1 , 8 , 15 every 4 week subsequently , gemcitabine monotherapy . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Gemcitabine Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; nonsmall cell lung cancer , stage IIIb ( effusion ) stage IV measurable disease ; ECOG PS 2 ; adequate organ function . prior chemotherapy systemic antitumor therapy ; hypersensitivity erlotinib ; condition contraindicating use study medication and/or impair interpretation result and/or lead treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>